Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2007-04-03
2007-04-03
Gambel, Phillip (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C435S007240, C435S029000
Reexamination Certificate
active
10299946
ABSTRACT:
The invention provides methods of monitoring amyotrophic lateral sclerosis (ALS) disease development or progression and monitoring an ALS therapy by determining the level of HLA-DR expression by CD14+ monocytes and/or the percentage of CD16+ cells in the population of CD14+ cells and/or the number of CD14+/CD16+ cells in peripheral blood of an individual with ALS. The invention is also directed to methods for decreasing the number of circulating CD14+ monocytes and/or the population of CD14+/CD16+ cells and/or the number of CD14+/CD16+ cells in an individual with ALS. The invention is also directed to methods of screening for agents which decrease the population of CD14+ monocytes with elevated HLA-DR expression and/or the population of CD14+/CD16+ cells and/or the number of CD14+/CD16+ cells in an individual with ALS.
REFERENCES:
patent: 4935449 (1990-06-01), Bey et al.
patent: 5498522 (1996-03-01), Porter
patent: 6638506 (2003-10-01), Schubert
patent: 7105183 (2006-09-01), McGrath
patent: WO 99/21542 (1999-05-01), None
patent: WO 99/29731 (1999-06-01), None
patent: WO 00/74718 (2000-12-01), None
Zhang et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (ALS). Journal of Neuroimmunology. 2005;159:215-224.
Bensimon, G. et al., “A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis” (1994) New Eng. J. Med. 330:858-591.
Deng, H. et al., “Amyotrophic Lateral Sclerosis and Structural Defects in Cu,Zn Superoxide Dismutase” (1993) Science 261:1047-1051.
Ferrante. R. et al., “Increased 3-Nitrotyrosine and Oxidative Damage in Mice with a Human Copper/Zinc Superoxide Dismutase Mutation” (1997) Ann. Neurol. 42(3):326-334.
Ferrante, R. et al., “Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis” (1997) J. Neurochem. 69:2064-2074.
Gredal, O. et al., “Muscarinic, N-Methyl-D-Aspartate (NMDA) and Benzodiazepine Receptor Binding Sites in Cortical Membranes from Amyotrophic Lateral Sclerosis Patients” (1996) J. Neurol. Sci. 143:121-125.
Gurney, M. et al., “Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation” (1994) Science 264:1772-1775.
Hall, E. et al., “Relationship of Oxygen Radical-Induced Lipid Perioxidative Damage to Disease Onset and Progression in a Transgenic Model of Familial ALS” (1998) J. Neurosci. Res. 53:66-77.
International Search Report mailed on Aug. 29, 2003, for PCT patent application No. PCT/US02/37178, filed Nov. 18, 2002, 8 pages.
Kalra, S. et al., “Biological Markers in the Diagnosis and Treatment of ALS” (1999) J. Neurol. Sci. 165:S27-S32.
Kramer, D. et al., “Use of 4-Fluoro-L-Ornithine to Monitor Metabolic Flux Through the Polyamine Biosynthetic Pathway” (1995) Biochem. Pharmacol. 50:1433.
Lacomblez, L. et al., “Dose-Ranging Study of Riluzole in Amyotrphic Lateral Sclerosis” (1996) Lancet 347:1425-1431.
Marton, L. and Pegg, A., “Polyamines As Targets for Therapeutic Intervention” (1995) Ann. Rev. Pharm. Toxicol. 35:55-91.
McGeer, P. et al., “Reactions of the Immune System in Chronic Degenerative Neurological Diseases” (1991) Can. J. Neurol. Sci. 18:376-379.
McGeer et al., (1989) Clinical and Investigative Medicine 12(suppl.4):B43.
Mukhopadhyaya, R. et al., “Effects of Bis(benzyl)polyamine Analogs on Leishmania donovani Promastigotes” (1995) Exp. Parasit. 81:39-46.
Olivera, A. et al., “Expression of HLA-DR in Pheripheral Nerve of Amyotrophic Lateral Sclerosis” (1994) Arq. Neuropsiquiatr. 52:493-500.
O'Sullivan, M. et al., “Polyamine Derivatives as Inhibitors of Trypanothione Reductase and Assessment of their Trypanocidal Activities” (1997) Bioorg. Med. Chem. 5:2145-2155.
Rosen, D et al., “Mutations in Cu/Zn Superoxide Dismutase Gene Are Associated with Familial Amyotrophic Lateral Slerosis” (1993) Nature 362:59-62.
Rothstein, J. et al., “Abnormal Excitatory Amino Acid Metabolism in Amyotrophic Lateral Sclerosis” (1990) Ann. Neurol. 28:18-25.
Rowland, L. et al., “Amyotrophic Lateral Sclerosis” (2001) N. Eng. J. Med. 344:1688-1700.
Schubert and Schwan, (1995) Neuroscience Letters 198:29-32.
Shaw, P. et al., CSF and Plasma Amino Acid Levels in Motor Neuron Disease: Elevation of CSF Glutamate in a Subset of Patients (1995) Neurodegeneration 4:209-216.
Troost, D. et al., “Immunohistological Alterations in Muscle of Patients with Amyotrophic Lateral Sclerosis: Mononuclear Cell Phenotypes and Expression of MHC Products” (1992) Clin. Neuropathol. 11:115-120.
Virgo, L. et al., “Induction of the Immediate Early Gene c-jun in Human Spinal Cord in Amyotrophic Lateral Sclerosis with Concomitant Loss of NMDA Receptor NR-1 and Glycine Transporter mRNA” (1995) Brain Res. 676:196-204.
Monk, P.N. and P.J. Shaw, “ALS: life and death in a bad neighborhood,” Nature Medicine, vol. 12, No. 8, pp. 885-887 (2006).
Marton Laurence J.
McGrath Michael
Ramesh Tennore M.
Scott Sean
Cooley Godward Kronish LLP
Crowder Chun
Gambel Phillip
Pathologica, LLC
LandOfFree
Screening for agents effective in decreasing abnormal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening for agents effective in decreasing abnormal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening for agents effective in decreasing abnormal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784373